SCHEMBL4693706

SCHEMBL4693706

O=CC(=C(c1ccccc1)c1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
TDP1 Q9NUW8 3/20 0.52
MAPK1 P28482 2/20 0.52
CES1 P23141 3/20 0.42
TSHR P16473 3/20 0.42
CES2 O00748 2/20 0.42
DAO P14920 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
CA2 P00918 3/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA9 Q16790 2/20 0.41
AKR1C1 Q04828 1/20 0.40
AKT1 P31749 1/20 0.39
CYP3A4 P08684 2/20 0.39
MAPT P10636 2/20 0.39
CA4 P22748 2/20 0.39
POLB P06746 1/20 0.39
PARP1 P09874 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9859507 0.88 MEN1 (0.42) ALDH1A1TDP1MAPK1CES1CES2
SCHEMBL9615016 0.87 ALDH1A1 (0.59) ALDH1A1TDP1MAPK1CES1TSHR
SCHEMBL9615018 0.87 ALDH1A1 (0.59) ALDH1A1TDP1MAPK1CES1TSHR
SCHEMBL2832454 0.80 ALDH1A1 (0.52) ALDH1A1TDP1MAPK1CES1TSHR
SCHEMBL2832450 0.80 ALDH1A1 (0.52) ALDH1A1TDP1MAPK1CES1TSHR
SCHEMBL2832453 0.80 ALDH1A1 (0.52) ALDH1A1TDP1MAPK1CES1TSHR
SCHEMBL9592340 0.79 ALDH1A1 (0.47) ALDH1A1TDP1MAPK1MAPTPOLB
SCHEMBL10456489 0.78 ALDH1A1 (0.50) ALDH1A1TDP1MAPK1CES1TSHR
SCHEMBL1824861 0.76 TCF4 (0.58) ALDH1A1TDP1MAPK1CES1TSHR
SCHEMBL1824858 0.76 TCF4 (0.58) ALDH1A1TDP1MAPK1CES1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1284734-B1 ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS CUREGENICS LTD (IL) 2008-05-21 EP disclosed
US-6949565-B2 Protein kinase inhibitors DEVELOGEN ISRAEL LTD. (IL) 2005-09-27 US disclosed
EP-1284734-A4 PROTEIN KINASE INHIBITORS PEPTOR LTD (IL) 2004-03-10 EP disclosed
US-20040019077-A1 Heterocyclic imines such as N1-(8-sulfonamide-5-isoquinoline)-N2-(3,3-diphenyl-2-propenyl) -ethylenediamine, used for prophylaxis and diagnosis of cancers, diabetes, cardiovascular and nervous system disorders, autoimmune diseases or obesity CUREGENICS LTD. (IL) 2004-01-29 US disclosed
EP-1284734-A1 PROTEIN KINASE INHIBITORS Peptor Ltd. (IL) 2003-02-26 EP disclosed
WO-2001091754-A1 PROTEIN KINASE INHIBITORS PEPTOR LTD. (IL) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019077-A1 Heterocyclic imines such as N1-(8-sulfonamide-5-isoquinoline)-N2-(3,3-diphenyl-2-propenyl) -ethylenediamine, used for prophylaxis and diagnosis of cancers, diabetes, cardiovascular and nervous system disorders, autoimmune diseases or obesity CHKB, MAP4K2, PKN2 ALDH1A1 3992/4885TDP1 1617/4885MAPK1 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.